The National Institute for Health and Care Excellence (NICE) has approved a combination of Imbruvica (ibrutinib) and venetoclax for all untreated chronic lymphocytic leukaemia (CLL) patients in England. The oral, fixed-duration combination treatment for adult CLL patients has been approved as first-line therapy and has been shown to be more effective than existing treatments. NICE’s […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!